Richard Gregory, Ph.D.
Former Executive Vice President and Chief Scientific Officer, ImmunoGen

Dr. Gregory received his Ph.D. in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology. In 1989 he joined Genzyme Corporation, where he spent the next 25 years in positions of increasing responsibility. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) protein and to determine the molecular defect caused by the most common mutation of CFTR. This work led to the founding of Genzyme’s gene therapy platform, which he led until 2001. Dr. Gregory then became Senior Vice President and Head of Research for Genzyme Corporation where he led early R&D, from discovery to development, in all therapeutic areas and platforms. In 2011, following the acquisition of Genzyme, he was appointed Head of the Sanofi-Genzyme R&D Center. In January of 2015 Dr. Gregory joined ImmunoGen, where he was responsible for research leading to new antibody based therapeutics to address the unmet needs of patients with cancer. Since September of 2019 Dr. Gregory has been an independent consultant. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Dr. Gregory is a Fellow of the American Institute for Medical and Biological Engineering.